This Week at PeptideChat
Our rotating picks — what we're highlighting in peptides, stacks, vendors, and the latest research.
Peptide of the Week
Retatrutide
Retatrutide is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Stack of the Week
CagriSema
A combination of a long-acting amylin analog with a GLP-1 agonist to enhance satiety and appetite suppression for weight loss.
Vendor of the Week
Peptide Sciences
A long-running research-peptide supplier often cited for third-party testing and certificates of analysis. Always verify current COAs and purity yourself — an educational spotlight, not an endorsement.
Hottest New Peptides
Petrelintide
Petrelintide is a long-acting amylin analog in phase 2/3 development for weight management, notable for producing meaningful weight loss with markedly less gastrointestinal burden than incretin-based drugs.
Amycretin (Zenagamtide)
Amycretin — now assigned the international nonproprietary name zenagamtide — is a single peptide that agonizes both the GLP-1 and amylin receptors, combining two distinct appetite pathways in one molecule.
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
Retatrutide
Retatrutide is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Maridebart Cafraglutide (MariTide)
MariTide is a once-monthly peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor — the opposite GIP strategy from tirzepatide, and the most mechanistically unusual drug in late-stage obesity development.